{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:45:42Z","timestamp":1781289942655,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.03.094","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T01:00:26Z","timestamp":1491958826000},"page":"5397-5402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Advancing new vaccines against pandemic influenza in low-resource countries"],"prefix":"10.1016","volume":"35","author":[{"given":"Francesco","family":"Berlanda Scorza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.094_b0005","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.vaccine.2017.03.094_b0010","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0b013e3181bc23fd","article-title":"Influenza is a major contributor to childhood pneumonia in a tropical developing country","volume":"29","author":"Brooks","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.03.094_b0015","unstructured":"Influenza vaccines \u2014 United States, 2016\u201317 influenza season n.d. <http:\/\/www.cdc.gov\/flu\/protect\/vaccine\/vaccines.htm>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0020","unstructured":"US Centers for Disease Control and Prevention\u2019s US Outpatient Influenza-like Illness Surveillance Network \u2013 Weekly U.S. Influenza Surveillance Report n.d. <http:\/\/www.cdc.gov\/flu\/weekly\/>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0025","doi-asserted-by":"crossref","first-page":"e92153","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012\u201313 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.094_b0030","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0035","unstructured":"Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO n.d. <http:\/\/www.who.int\/influenza\/human_animal_interface\/H5N1_cumulative_table_archives\/en\/>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0040","unstructured":"WHO. Global Action Plan for Influenza Vaccines (GAP) n.d. <http:\/\/www.who.int\/influenza_vaccines_plan\/en\/>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0045","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/S0140-6736(06)69895-4","article-title":"Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918\u201320 pandemic: a quantitative analysis","volume":"368","author":"Murray","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.094_b0050","unstructured":"PATH\u2019s Center for Vaccine Innovation and Access (CVIA) - Influenza n.d. <http:\/\/sites.path.org\/cvia\/our-disease-targets\/influenza\/>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0055","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1016\/j.vaccine.2016.08.052","article-title":"Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults","volume":"34","author":"Anh","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0060","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1016\/j.vaccine.2016.08.055","article-title":"Clinical testing of an inactivated influenza A\/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam","volume":"34","author":"Phan","year":"2016","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.03.094_b0065","doi-asserted-by":"crossref","first-page":"A34","DOI":"10.1016\/j.vaccine.2011.04.118","article-title":"Development of pandemic influenza vaccine production capacity in Viet Nam","volume":"29","author":"Hoa","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0070","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/erv.12.76","article-title":"PATH\u2019s Influenza Vaccine Project team. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries","volume":"11","author":"Neuzil","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.094_b0075","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1016\/j.vaccine.2016.07.046","article-title":"Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers","volume":"34","author":"Wahid","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0080","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1016\/j.vaccine.2014.06.045","article-title":"Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing","volume":"32","author":"Donis","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0085","unstructured":"WHO SAGE Report of the H5N1 SAGE Working Group to the April 2009 meeting of the Strategic Advisory Group of Experts n.d. <http:\/\/www.who.int\/immunization\/sage\/SAGE_H5N1_26Mayb.pdf>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0090","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(00)00395-9","article-title":"Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans","volume":"19","author":"Treanor","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0095","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/592172","article-title":"Safety and immunogenicity of an inactivated influenza A\/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial","volume":"198","author":"Keitel","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.094_b0100","doi-asserted-by":"crossref","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2017.03.094_b0105","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2006.01.015","article-title":"An MF59-adjuvanted inactivated influenza vaccine containing A\/Panama\/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A\/Fujian\/2002 than a subunit and a split influenza vaccine","volume":"24","author":"Giudice","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0110","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.03.094_b0115","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1016\/j.vaccine.2013.10.033","article-title":"Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A\/H1N1 (H1N1pdm09) vaccine","volume":"31","author":"Rouleau","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0120","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.094_b0125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.094_b0130","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1016\/j.vaccine.2009.08.110","article-title":"Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults","volume":"27","author":"Leroux-Roels","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0135","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/INF.0b013e3181861dd7","article-title":"Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children","volume":"27","author":"Vajo","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.03.094_b0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/jit498","article-title":"Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population","volume":"209","author":"van der Velden","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.094_b0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.094_b0150","unstructured":"Sanofi Pasteur Influenza Virus Vaccine, H5N1 n.d. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM112836.pdf>."},{"key":"10.1016\/j.vaccine.2017.03.094_b0155","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/21645515.2015.1069931","article-title":"Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine","volume":"11","author":"Rudenko","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2017.03.094_b0160","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.094_b0165","doi-asserted-by":"crossref","first-page":"6798","DOI":"10.1016\/j.vaccine.2014.09.070","article-title":"Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine","volume":"32","author":"Babu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.094_b0170","unstructured":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) \u2014 United States, 2014\u201315 Influenza Season n.d. <http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6332a3.htm#Groups_Recommended_Vaccination_Timing_Vaccination> [accessed March 20, 2015]."},{"key":"10.1016\/j.vaccine.2017.03.094_b0175","doi-asserted-by":"crossref","first-page":"30350","DOI":"10.2807\/1560-7917.ES.2016.21.38.30350","article-title":"Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?","volume":"21","author":"Penttinen","year":"2016","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2017.03.094_b0180","doi-asserted-by":"crossref","first-page":"30366","DOI":"10.2807\/1560-7917.ES.2016.21.40.30366","article-title":"Letter to the editor: regarding the editorial by Penttinen and Friede","volume":"21","author":"Fry","year":"2016","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2017.03.094_b0185","doi-asserted-by":"crossref","first-page":"30346","DOI":"10.2807\/1560-7917.ES.2016.21.38.30346","article-title":"Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds \u2013 a nationwide cohort study Finland, influenza season 2015\/16","volume":"21","author":"Nohynek","year":"2016","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2017.03.094_b0190","doi-asserted-by":"crossref","first-page":"30348","DOI":"10.2807\/1560-7917.ES.2016.21.38.30348","article-title":"Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015\/16 end-of-season results","volume":"21","author":"Pebody","year":"2016","journal-title":"Eurosurveillance"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T11:24:09Z","timestamp":1536060249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17304462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17304462"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.094","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing new vaccines against pandemic influenza in low-resource countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}